LOCALLY ADVANCED PANCREATIC ADENOCARCINOMA
Clinical trials for LOCALLY ADVANCED PANCREATIC ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new LOCALLY ADVANCED PANCREATIC ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for LOCALLY ADVANCED PANCREATIC ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New cocktail aims to starve pancreatic tumors
Disease control CompletedThis early-phase trial tests two drugs together in 15 people with advanced pancreatic cancer. One drug, calaspargase pegol-mknl, lowers a nutrient that cancer cells need to grow. The other, cobimetinib, blocks a protein that helps cancer cells survive. The goal is to find a safe …
Matched conditions: LOCALLY ADVANCED PANCREATIC ADENOCARCINOMA
Phase: PHASE1 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Four-Drug cocktail aims to shrink pancreatic tumors before surgery
Disease control CompletedThis phase II trial tests whether a combination of four chemotherapy drugs—paclitaxel protein bound, gemcitabine, cisplatin, and hydroxychloroquine—given before surgery can improve outcomes for people with pancreatic cancer that has not spread. The study focuses on patients whose…
Matched conditions: LOCALLY ADVANCED PANCREATIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: HonorHealth Research Institute • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Immune cells armed with antibody take on pancreatic cancer
Disease control CompletedThis trial tested a new treatment called EGFR BATs for people with advanced pancreatic cancer. The treatment uses a patient's own immune cells, armed with a special antibody, to target cancer cells. The study included 22 participants who had already received chemotherapy. The goa…
Matched conditions: LOCALLY ADVANCED PANCREATIC ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: University of Virginia • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Triple threat: new combo aims to stop pancreatic cancer spread
Disease control CompletedThis phase II trial tested a combination of a pancreatic cancer vaccine (GVAX), an immunotherapy drug (pembrolizumab), and focused radiation (SBRT) in 58 patients with locally advanced pancreatic cancer. The goal was to see if this approach could delay the spread of the cancer to…
Matched conditions: LOCALLY ADVANCED PANCREATIC ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC